Overall survival ‐ not reported · people with chronic lymphocytic leukaemia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life ‐ not reported · people with chronic lymphocytic leukaemia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Grades 3 and 4 adverse events ‐ not reported · people with chronic lymphocytic leukaemia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Progression‐free survival · people with chronic lymphocytic leukaemia
It is very uncertain whether anti‐CD52 mAb maintenance therapy changes progression‐free survival compared with observation (very low certainty).
1 finding from 1 review
Treatment‐related mortality ‐ not reported · people with chronic lymphocytic leukaemia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life · people with chronic lymphocytic leukaemia
1 finding from 1 review
Treatment discontinuation · people with chronic lymphocytic leukaemia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All adverse events – not reported · people with chronic lymphocytic leukaemia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Grades 3 and 4 adverse events · people with chronic lymphocytic leukaemia
Anti‐CD20 mAb maintenance therapy may leads to higher grade 3/4 adverse events compared with observation (low certainty).
1 finding from 1 review
Progression‐free survival · people with chronic lymphocytic leukaemia
Anti‐CD20 mAb maintenance therapy probably leads to lower progression‐free survival compared with observation (moderate certainty).
1 finding from 1 review
Treatment‐related mortality · people with chronic lymphocytic leukaemia
Anti‐CD20 mAb maintenance therapy showed no clear difference in treatment‐related mortality compared with observation (low certainty).
1 finding from 1 review
Treatment discontinuation · people with chronic lymphocytic leukaemia
Anti‐CD20 mAb maintenance therapy showed no clear difference in treatment discontinuation compared with observation (low certainty).
1 finding from 1 review
All adverse events · people with chronic lymphocytic leukaemia
Anti‐CD20 mAb maintenance therapy may leads to higher all adverse events compared with observation (low certainty).
1 finding from 1 review
Overall survival · people with chronic lymphocytic leukaemia
Immunomodulatory drug maintenance therapy showed no clear difference in overall survival compared with placebo/observation (moderate certainty).
1 finding from 1 review
Health‐related quality of life ‐ not reported · people with chronic lymphocytic leukaemia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall survival (at 36 months) · people with newly diagnosed multiple myeloma ineligible for transplant
Summary of findings table ‐ Daratumumab plus standard therapy probably leads to lower overall survival (at 36 months) compared with standard therapy (moderate certainty).
1 finding from 1 review
Progression‐free survival (PSF) · people with newly diagnosed multiple myeloma ineligible for transplant
Summary of findings table ‐ Daratumumab plus standard therapy probably leads to lower progression‐free survival (at 24 months) compared with standard therapy (moderate certainty).
1 finding from 1 review
Health‐related quality of life European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ‐C30). Scale from: 0 to 100 (a higher score means a better outcome) · people with newly diagnosed multiple myeloma ineligible for transplant
1 finding from 1 review
Mortality within the longest · people with newly diagnosed multiple myeloma ineligible for transplant
Summary of findings table ‐ Daratumumab plus standard therapy probably leads to lower on‐study mortality (longest available compared with standard therapy (moderate certainty).
1 finding from 1 review
Serious adverse events at longest · people with newly diagnosed multiple myeloma ineligible for transplant
Summary of findings table ‐ Daratumumab plus standard therapy probably leads to higher serious adverse events (longest available compared with standard therapy (moderate certainty).
1 finding from 1 review